Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL1332 ophthalmic solution in healthy volunteers
NCT06978244Phase 1Active, not recruiting
- Sponsor
- Bausch + Lomb
- Start
- Jul 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial comparing BL1332 ophthalmic solution with BL1332 vehicle (2 arms). Primary endpoints: Dose-Limiting Toxicities at 6 months, Treatment-Emergent Adverse Events at 6 months and 10 more. Started Jul 2025; status: active, not recruiting.
02
Drugs
BL1332
Beyond the preview
Go deeper on NCT06978244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06978244.